Suraksha Diagnostic Ltd
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution.[1]
- Market Cap ₹ 1,685 Cr.
- Current Price ₹ 324
- High / Low ₹ 449 / 231
- Stock P/E 54.4
- Book Value ₹ 40.6
- Dividend Yield 0.00 %
- ROCE 17.5 %
- ROE 15.9 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 7.98 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 9.86% over past five years.
- Company has a low return on equity of 12.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 158 | 140 | 223 | 190 | 219 | 252 | |
| 123 | 115 | 175 | 143 | 146 | 171 | |
| Operating Profit | 34 | 25 | 48 | 47 | 73 | 81 |
| OPM % | 22% | 18% | 22% | 25% | 33% | 32% |
| 2 | -1 | 2 | 1 | 1 | 4 | |
| Interest | 2 | 2 | 2 | 10 | 10 | 8 |
| Depreciation | 13 | 16 | 15 | 32 | 33 | 35 |
| Profit before tax | 21 | 6 | 33 | 7 | 31 | 41 |
| Tax % | 28% | -1% | 28% | 10% | 26% | 25% |
| 15 | 6 | 24 | 6 | 23 | 31 | |
| EPS in Rs | 220.43 | 93.33 | 344.20 | 94.49 | 342.46 | 6.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 4% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 9% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 12% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 10 |
| Reserves | 111 | 118 | 141 | 147 | 171 | 201 |
| 13 | 18 | 21 | 99 | 92 | 89 | |
| 42 | 28 | 32 | 28 | 30 | 33 | |
| Total Liabilities | 173 | 171 | 201 | 281 | 300 | 334 |
| 128 | 119 | 119 | 195 | 212 | 223 | |
| CWIP | 0 | 0 | 1 | 2 | 1 | 10 |
| Investments | 5 | 5 | 0 | 0 | 0 | 1 |
| 39 | 46 | 80 | 84 | 87 | 99 | |
| Total Assets | 173 | 171 | 201 | 281 | 300 | 334 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 31 | 24 | 42 | 44 | 60 | 63 | |
| -20 | -28 | -44 | -21 | -35 | -40 | |
| -10 | 3 | 1 | -24 | -25 | -24 | |
| Net Cash Flow | 1 | -1 | -0 | -1 | 0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 14 | 16 | 12 | 9 | 15 | 20 |
| Inventory Days | 93 | 62 | 38 | 82 | 89 | 100 |
| Days Payable | 227 | 177 | 84 | 187 | 193 | 169 |
| Cash Conversion Cycle | -120 | -99 | -34 | -96 | -89 | -49 |
| Working Capital Days | -35 | -2 | -4 | -17 | -12 | -1 |
| ROCE % | 8% | 23% | 9% | 17% | 18% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 2h
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
3h - Suraksha Diagnostic launches Eastern India's largest genomics lab with ₹22 Cr investment, plans ₹46 Cr more.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6h - Certificate from RTA pursuant to Reg. 74(5) of SEBI (Depositories and Participants) Regulations, 2018
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Jun
-
Closure of Trading Window
20 Jun - Trading window closed from 1 July 2025 till 48 hours post Q1 results announcement.
Concalls
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Dec 2024TranscriptNotesPPT
Business Model[1][2]
a) Integrated Services: Offers a one-stop solution for pathology, radiology, and medical consultancy services.
b) Comprehensive Testing: Provides 2,300+ diagnostic tests, ranging from routine pathology to advanced radiology.
c) Hub and Spoke Model: Operates through a central reference lab, 8 satellite labs, and a network of diagnostic and collection centers for efficient sample processing and service delivery.
d) Omni-channel Consultation: Combines online and offline medical consultation services, leveraging its polyclinics with 750+ doctors.
e) B2C-Focused Revenue Model: Primarily serves individual patients, with some revenue from B2B contracts.
Diagnostic Test Data[1][3]
a) Pathology Tests:
788 Routine Tests: Basic biochemistry, hematology.
664 Specialized Tests: Advanced biochemistry, histopathology, molecular pathology.
b) Radiology Tests:
766 Basic/Intermediate Tests: X-rays, USG, CT scans.
119 Advanced Tests: MRI scans, specialized CT scans.
Equipment: 24 CT and 13 MRI machines.
c) Testing Volume:
Q1 FY25: 1.58 million tests (0.28 million patients).
FY24: 5.98 million tests (1.14 million patients).
Geographical Presence [4]
West Bengal is their core market accounting for 95.34% of Q1 FY25 revenue. It also has a presence across Bihar, Assam, and Meghalaya. As of FY24, the company has a 1.15-1.3% market share in eastern India.